SequelSEC

Twist Bioscience Corp TWST

Biological Products, (No Diagnostic Substances) · CIK 0001581280 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$431.80M
Fiscal year ended 2026-06-30
Operating income
-$144.98M
Fiscal year ended 2026-06-30
Free cash flow
-$93.12M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$2.32BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-03-31
Float per share$37.94Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue6.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity4.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-03-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-09-30 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue21.3%13th
FCF margin-20.1%75th
Operating margin-36.2%74th
Net margin-20.6%74th
Gross margin50.7%32th
SBC / revenue17.1%32th
CapEx / revenue7.4%66th
Revenue YoY growth20.3%61th
Current ratio3.64x42th

Twist Bioscience Corp (TWST) reported revenue of $431.80M and net income of -$136.72M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Twist Bioscience Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Twist Bioscience Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$431.80M
Cost of revenue$207.41M
Gross profit$224.38M
Operating income-$144.98M
Net income-$136.72M
Research & development$71.86M
Weighted-average diluted sharesUnavailable
Pretax income-$135.85M
Income tax expense$864.00K
Diluted EPSUnavailable
Selling, general & administrative$290.29M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Twist Bioscience Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$117.44M
Total assets$672.44M
Current assets$321.30M
Total liabilities$226.70M
Current liabilities$120.26M
Total equity incl. NCI$445.74M
Temporary (mezzanine) equityUnavailable
Inventory$35.16M
Accounts receivable$65.06M
Goodwill$82.20M
Long-term debtUnavailable
Accounts payable$17.04M

Cash flow

Twist Bioscience Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$53.07M
Capital expenditures$40.05M
Investing cash flow-$45.24M
Financing cash flow$13.80M
Net change in cash-$84.34M
Stock-based compensation$66.47M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$25.39M

Derived

Twist Bioscience Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$93.12M
Gross margin52.0%
Operating margin-33.6%
FCF margin-21.6%
SBC / revenue15.4%
Current ratio2.67x
Revenue YoY growth19.2%
Net margin-31.7%
R&D / revenue16.6%
CapEx / revenue9.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TWST in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-Q/A · Filed 2026-02-26View SEC filing
10-Q · Filed 2026-02-02View SEC filing
10-K · Filed 2025-11-17View SEC filing
10-Q · Filed 2025-08-04View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.